This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

By focusing on chips and pharmaceuticals, Trump could squeeze US allies in Asia, including Taiwan, South Korea and Japan.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and ...

The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...